Back to search

Article

Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutation

2021-09-17

Abstract excerpt

<h4>Background: </h4> Langerhans cell histiocytosis (LCH) has been defined as a disorder driven by misguided myeloid differentiation, with up to 50% of cases harboring the BRAF-V600E mutation. Salvage treatment with LCH refractory to vinblastine and steroid regimen is intractable. Vemurafenib is safe and effective in children with refractory BRAF-V600E -positive LCH, but the disease always reactivates with the wit...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
c6b822b3-fbfa-5f2a-a242-098c48470ee5
DOI
10.21203/rs.3.rs-888920/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Failure of salvage vemurafenib therapy for refractory multisystem Langerhans cell histiocytosis with BRAF-V600E mutationDOI 10.21203/rs.3.rs-888920/v1
Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature.Semantic proximity
Refractory multisystem Langerhans cell histiocytosis in an infant: use of vemurafenib as a therapeutic option.Semantic proximity
Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study.Semantic proximity
Vemurafenib provides a rapid and robust clinical response in paediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease based on ddPCR using cell-free circulating DNASemantic proximity
Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review.Semantic proximity
Early association of Vemurafenib to standard chemotherapy in multisystemic Langerhans cell histiocytosis in a newborn: take the chance for a better outcome?Semantic proximity
Targeted Therapy with Vemurafenib in Brazilian Children with Refractory Langerhans Cell Histiocytosis: Two Case Reports and a Comprehensive ReviewSemantic proximity
Langerhans cell histiocytosis in children: from the bench to bedside for an updated therapy.Semantic proximity
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.Semantic proximity
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.Semantic proximity
Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis.Semantic proximity
[Updated AWMF Guideline on the Diagnosis and Treatment of Langerhans cell Histiocytosis in Children and Adolescents].Semantic proximity
Select a neighboring publication to make it the new centre.